S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10

Advanced Oncotherapy Share Forecast, Price & News

GBX 37.74
-0.26 (-0.67 %)
(As of 10/22/2021 04:26 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume142,723 shs
Average Volume205,157 shs
Market Capitalization£165.89 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AVO News and Ratings via Email

Sign-up to receive the latest news and ratings for Advanced Oncotherapy and its competitors with MarketBeat's FREE daily newsletter.

Advanced Oncotherapy logo

About Advanced Oncotherapy

Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, selling, and maintaining proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Medical Devices
Year Founded

Sales & Book Value

Annual Sales
Cash Flow
GBX 0.20 per share
Book Value
GBX 13.20 per share





Market Cap
£165.89 million
Next Earnings Date
Not Optionable


Overall MarketRank

0.80 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Advanced Oncotherapy (LON:AVO) Frequently Asked Questions

What stocks does MarketBeat like better than Advanced Oncotherapy?

Wall Street analysts have given Advanced Oncotherapy a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Advanced Oncotherapy wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Advanced Oncotherapy's earnings last quarter?

Advanced Oncotherapy plc (LON:AVO) posted its quarterly earnings results on Monday, June, 29th. The company reported ($9.83) earnings per share for the quarter, missing the Zacks' consensus estimate of ($8.90) by $0.93.
View Advanced Oncotherapy's earnings history

How has Advanced Oncotherapy's stock been impacted by COVID-19 (Coronavirus)?

Advanced Oncotherapy's stock was trading at GBX 32.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AVO shares have increased by 16.1% and is now trading at GBX 37.75.
View which stocks have been most impacted by COVID-19

Who are Advanced Oncotherapy's key executives?

Advanced Oncotherapy's management team includes the following people:
  • Dr. Michael Jeffrey Sinclair, Exec. Chairman (Age 78, Pay $554.93k)
  • Mr. Nicolas Serandour, CEO & Exec. Director
  • Prof. Stephen Myers, Exec. Director (Age 74, Pay $255.69k)
  • Mr. Ed Lee, COO & Pres of Europe
  • Mr. Graham Pughe, Sr. Vice-Pres of Accounting
  • Dr. Manuel Gallas, Director of Technical & Engineering
  • Mr. David Navas, VP of Investor and PR
  • Ms. Bridget Biggar, Director of HR
  • Ms. Donatella Ungaro, Managing Director of ADAM
  • Ms. Marina Giunta, Head of Physics Group

What other stocks do shareholders of Advanced Oncotherapy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Advanced Oncotherapy investors own include UK Oil & Gas (UKOG), Avesoro Resources (ASO), Oxford Biomedica (OXB), BMR Group (BMR), GW Pharmaceuticals (GWPH), Lancashire (LRE), Sirius Minerals (SXX), Renishaw (RSW), Scancell (SCLP) and Tullow Oil (TLW).

What is Advanced Oncotherapy's stock symbol?

Advanced Oncotherapy trades on the London Stock Exchange (LON) under the ticker symbol "AVO."

How do I buy shares of Advanced Oncotherapy?

Shares of AVO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Advanced Oncotherapy's stock price today?

One share of AVO stock can currently be purchased for approximately GBX 37.75.

How much money does Advanced Oncotherapy make?

Advanced Oncotherapy has a market capitalization of £165.89 million.

How many employees does Advanced Oncotherapy have?

Advanced Oncotherapy employs 2,500 workers across the globe.

What is Advanced Oncotherapy's official website?

The official website for Advanced Oncotherapy is www.advancedoncotherapy.com.

Where are Advanced Oncotherapy's headquarters?

How can I contact Advanced Oncotherapy?

Advanced Oncotherapy's mailing address is Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom. The company can be reached via phone at +44-20-36178728.

This page was last updated on 10/24/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.